Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(11):1730–1733. doi: 10.1038/bjc.1996.622

Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours.

J M Sargent 1, A W Elgie 1, C J Williamson 1, C G Taylor 1
PMCID: PMC2077213  PMID: 8956785

Abstract

Enhanced DNA repair has been observed in cisplatin-resistant ovarian cancer cell lines. This resistance can be modulated, on co-incubation with aphidicolin in established cell lines and animal tumour models, by inhibiting DNA polymerases. We describe a study of the in vitro modulation effect of aphidicolin on cisplatin and carboplatin using fresh cells harvested from biopsy samples or ascitic fluids from 25 patients with ovarian adenocarcinoma. The MTT assay was used to measure cell survival after drug exposure. Aphidicolin (up to 30 microM) showed no cytotoxicity when tested alone. Forty-seven comparisons were made between drug with and without aphidicolin, and 37 (79%) cases demonstrated a significant increase in sensitivity to the platinum agents on co-incubation. Overall, there was a median 10-fold (range 1.64- to 58.5-fold) increase in sensitivity. When patients were grouped according to in vitro sensitivity to platinum, aphidicolin had a significantly greater effect in the "resistant' group, causing a median 13.5-fold increase in sensitivity compared with 2.4-fold in the "sensitive' group. Furthermore, a positive correlation between the LC50 for platinum and the corresponding fold increase in sensitivity suggests that aphidicolin overcomes platinum resistance in fresh cells from primary tumours. These results encourage the further development of this interesting compound.

Full text

PDF
1730

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beketic-Oreskovic L., Osmak M. Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells. Cancer Chemother Pharmacol. 1995;35(4):327–333. doi: 10.1007/BF00689453. [DOI] [PubMed] [Google Scholar]
  2. Boulton S., Pemberton L. C., Porteous J. K., Curtin N. J., Griffin R. J., Golding B. T., Durkacz B. W. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer. 1995 Oct;72(4):849–856. doi: 10.1038/bjc.1995.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chao C. C. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells. Eur J Pharmacol. 1994 Aug 16;268(3):347–355. doi: 10.1016/0922-4106(94)90059-0. [DOI] [PubMed] [Google Scholar]
  4. Damia G., Tagliabue G., Zucchetti M., Davoli E., Sessa C., Cavalli F., D'Incalci M. Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother Pharmacol. 1992;30(6):459–464. doi: 10.1007/BF00685597. [DOI] [PubMed] [Google Scholar]
  5. Dempke W. C., Shellard S. A., Fichtinger-Schepman A. M., Hill B. T. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro. Carcinogenesis. 1991 Mar;12(3):525–528. doi: 10.1093/carcin/12.3.525. [DOI] [PubMed] [Google Scholar]
  6. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 1990 Aug-Sep;2(8-9):275–280. [PubMed] [Google Scholar]
  7. Eastman A., Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry. 1988 Jun 28;27(13):4730–4734. doi: 10.1021/bi00413a022. [DOI] [PubMed] [Google Scholar]
  8. Gormley P. E., Bull J. M., LeRoy A. F., Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 1979 Mar;25(3):351–357. doi: 10.1002/cpt1979253351. [DOI] [PubMed] [Google Scholar]
  9. Hengstler J. G., Fuchs J., Oesch F. DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res. 1992 Oct 15;52(20):5622–5626. [PubMed] [Google Scholar]
  10. Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kaye S. B. Chemotherapy for ovarian cancer. Eur J Cancer. 1993;29A(4):632–635. doi: 10.1016/s0959-8049(05)80168-6. [DOI] [PubMed] [Google Scholar]
  12. Kaye S. B., Lewis C. R., Paul J., Duncan I. D., Gordon H. K., Kitchener H. C., Cruickshank D. J., Atkinson R. J., Soukop M., Rankin E. M. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992 Aug 8;340(8815):329–333. doi: 10.1016/0140-6736(92)91404-v. [DOI] [PubMed] [Google Scholar]
  13. Masuda H., Ozols R. F., Lai G. M., Fojo A., Rothenberg M., Hamilton T. C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 1988 Oct 15;48(20):5713–5716. [PubMed] [Google Scholar]
  14. Morgan R. J., Jr, Margolin K., Raschko J., Akman S., Leong L., Somlo G., Scanlon K., Ahn C., Carroll M., Doroshow J. H. Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy. J Clin Oncol. 1995 Sep;13(9):2238–2246. doi: 10.1200/JCO.1995.13.9.2238. [DOI] [PubMed] [Google Scholar]
  15. Newell D. R., Siddik Z. H., Gumbrell L. A., Boxall F. E., Gore M. E., Smith I. E., Calvert A. H. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1399–1405. doi: 10.1016/0277-5379(87)90126-x. [DOI] [PubMed] [Google Scholar]
  16. O'Dwyer P. J., Hamilton T. C., LaCreta F. P., Gallo J. M., Kilpatrick D., Halbherr T., Brennan J., Bookman M. A., Hoffman J., Young R. C. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol. 1996 Jan;14(1):249–256. doi: 10.1200/JCO.1996.14.1.249. [DOI] [PubMed] [Google Scholar]
  17. O'Dwyer P. J., Moyer J. D., Suffness M., Harrison S. D., Jr, Cysyk R., Hamilton T. C., Plowman J. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res. 1994 Feb 1;54(3):724–729. [PubMed] [Google Scholar]
  18. Ozols R. F. Chemotherapy for advanced epithelial ovarian cancer. Hematol Oncol Clin North Am. 1992 Aug;6(4):879–894. [PubMed] [Google Scholar]
  19. Perez R. P., Hamilton T. C., Ozols R. F., Young R. C. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer. 1993 Feb 15;71(4 Suppl):1571–1580. doi: 10.1002/cncr.2820710424. [DOI] [PubMed] [Google Scholar]
  20. Reed E., Ozols R. F., Tarone R., Yuspa S. H., Poirier M. C. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A. 1987 Jul;84(14):5024–5028. doi: 10.1073/pnas.84.14.5024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sargent J., Elgie A., Taylor C. G., Wilson J., Alton P., Hill J. G. The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay. Contrib Gynecol Obstet. 1994;19:64–75. [PubMed] [Google Scholar]
  22. Sessa C., Zucchetti M., Davoli E., Califano R., Cavalli F., Frustaci S., Gumbrell L., Sulkes A., Winograd B., D'Incalci M. Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst. 1991 Aug 21;83(16):1160–1164. doi: 10.1093/jnci/83.16.1160. [DOI] [PubMed] [Google Scholar]
  23. Wilson J. K., Sargent J. M., Elgie A. W., Hill J. G., Taylor C. G. A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J Cancer. 1990 Aug;62(2):189–194. doi: 10.1038/bjc.1990.258. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES